Creative Biostructure

Online Inquiry

Please type "biostructure" as the verification code.

MagHelix™ Zebrafish Screening Platforms

Zebrafish (Danio rerio) possesses the physiology complexity of mammalian animals and is one of the mostcommon vertebrate model organisms. Creative Biostructure establishes and provides the MagHelix™ Zebrafish Screening Platforms for scientific and medical research. Zebrafish can be used to study vertebrate development and gene function. On the other hand, it is also an excellent choice to model various diseases and screen novel drugs for medical and therapeutic research.

Phenotype based chemical screening in zebrafish Figure 1. Phenotype based chemical screening in zebrafish

Zebrafish larvae have been used increasingly within the last decade to assess the effects of chemical compounds. This is an ideal platform for in vivo compound testing due to its several specific features. Their small size makes their embryos and larvae dispensed in microtiter plates. Zebrafish has high fecundity so it is easy to obtain large sample numbers and it is transparent to facilitate noninvasive imaging. Moreover, they have permeability to small molecules which allows drug to administrate by immersion. There are four classes of zebrafish chemical screening assays: morphological screens (to screen chemical chemical genetics and toxicology), behavioral screens (ex. using swimming kinetics to quantify the effects of single compounds), fixed time-point/labeling assays (to obtain information on a cellular or tissue level) and fluorescence assays (reporter-based quantifications). There are various assays based on MagHelix™ Zebrafish Screening Platforms shown in the following table. Take cardiovascular toxicity test as an example, which is a key limiting factor in drug discovery. The one of the features that the zebrafish heart can be dissected rapidly and maintained ex vivo for several days makes zebrafish an excellent model for assessment of cardiovascular toxicity.

MagHelix™ Zebrafish Screening Platforms

Angiogenesis assay
mRNA expression marker (Each gene)
Toxicity tests General toxicity on survival rates of zebrafish embryo or larvae
Cardiotoxicity test in zebrafish
Toxicity test to development of motor neuron or dopaminergic neuron in zebrafish
Human Endothelial Cell (HUVEC) model Proliferation assay
Adhesion assay
Migration assay
Tube formation assay
Tg (Fli-1:EGFP) and Tg (Fli-1:nEGFP) transgenic zebrafish model Normal angiogenesis assay in larvae
Tg (Fli-1: EGFP) zebrafish fin regeneration model
Regenerative angiogenesis assay in adult zebrafish
Neurological disorder model Protective effect against H2O2 induced PC12 cell damage
Protective effect against H2O2 induced SH-SY5Y cell damage
Protective effect against L-glutaric acid (LGA) induced neuron cell death in zebrafish
Protective effect against MPTP or 6-OHDA induced dopaminergic neuron cell death in zebrafish (Parkinson's disease)
Protective effect against MPTP or 6-OHDA induced deficit of locomotor behavior in zebrafish (Parkinson's disease)
Protective effect against chemical induced epilepsy in zebrafish
Cardiovascular disease model Protective effect against chemotherapy drug induced cardiac damage in zebrafish
Protective effect against chemical induced induced cerebral hemorrhage in zebrafish
Skeletal disease model Bone anabolic effect in zebrafish
Immunological model Immunosuppressive effect on T cell in zebrafish

Creative Biostructure provides full range of services for drug discovery and drug design. Please feel free to contact us for a detailed quote.

Ordering Process

Ordering Process


  1. Jonathan R mathias, et al. Advances in zebrafish chemical screening technologies. Future Med Chem. 2012 Sep;4(14):1811-22.
  2. Kerrie L Taylor, et al. Small molecule screening in zebrafish: an in vivo approach to identifying new chemical tools and drug leads. Cell Commun Signal. 2010 Jun 12;8:11.
  3. Satish Srinivas Kitambi, et al. Small molecule screening platform for assessment of cardiovascular toxicity on adult zebrafish heart. BMC Physiol. 2012 Mar 26;12:3.